PALO ALTO, California, April 16 /PRNewswire/ --
Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the launch of the Cell Biosciences CB1000 protein analysis system, a next-generation platform for ultrasensitive characterization of cell signaling proteins. The CB1000 establishes a new standard for sensitivity, reproducibility, and ease-of-use for researchers studying signaling pathways in limited samples, such as small tumor biopsies and stem cells. The CB1000 will be unveiled at the American Association for Cancer Research (AACR) 100th Annual Meeting, April 18-22, 2009, in Denver, Colorado (booth 2039).
The CB1000 system measures phosphorylation events and other protein post-translational modifications using capillary-based nanofluidic immunoassays, and builds upon the fundamental technology of its predecessor, the Firefly(TM) 3000 system. The advanced design of the CB1000 system provides significant improvements in assay performance and automation, including a doubling of sample throughput. Assay reproducibility and stability have been increased through the incorporation of precise temperature control systems. In addition, the CB1000's software package, Compass(TM), features dramatic improvements in data analysis speed.
David Hirschberg, Ph.D., Director of the Human Immune Monitoring Center at Stanford University School of Medicine, recently completed a three-month evaluation of a prototype CB1000 system. This system represents an impressive step forward for Cell Biosciences' technology, noted Dr. Hirschberg. My group has been using the CB1000 system heavily - typically six days a week. We have been extremely pleased by the system's high level of performance and reliability.
The CB1000 is our first platform designed for broad distribution, added Tim Harkness, President and Chief Executive Officer at Cell Biosciences. We believe that the CB1000 will allow us to penetrate important new markets as we build our worldwide commercial infrastructure. We also believe that the CB1000 will enable our customers to gain novel insights into the causes and treatment of human disease.
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay products that reveal previously undetectable information about cellular control pathways. Our customers include leading institutions in the fields of cancer research, stem cell biology, and diabetes. Our products enable researchers to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Cell Biosciences is located in Palo Alto, California. For more information, visit www.cellbiosciences.com.
Walter Ausserer, Ph.D., Vice President of Marketing of Cell Biosciences, Inc., +1-650-618-7503, wausserer@cellbiosciences.com
Comments